NCT03952598View on ClinicalTrials.gov

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

PHASE2RecruitingINTERVENTIONAL

Enrollment

270

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

GliomaGliomasHigh Grade GliomaMalignant GliomaLow Grade Glioma

Interventions

DRUG

HP 13C Pyruvate

Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)

DEVICE

3T MRI scanner

Research proton MRS (1H-MRS) followed by DW-MRI

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | Biotech Hunter | Biotech Hunter